Abeona Therapeutics (ABEO) financial statements
Abeona Therapeutics reported revenue of $6M in fiscal 2025, up 23.2% a year over 9 years.
Net income was $71M and the operating margin -1536.9%, against -2686.3% in 2016.
Free cash flow was -$84M.
The diluted share count rose 4737% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Abeona Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $889,000 | $837,000 | $3M | — | $10M | $3M | $1M | $4M | — | $6M |
| Cost of revenue | — | — | — | — | — | — | — | — | — | $2M |
| Gross profit | — | — | — | — | — | — | — | — | — | $4M |
| Research and development | $11M | $17M | $39M | $49M | $30M | $39M | $29M | $31M | $34M | $27M |
| Selling, general and admin | $13M | $11M | $20M | $21M | $24M | $22M | $17M | $19M | $30M | $65M |
| Operating income | -$24M | -$28M | -$58M | -$77M | -$81M | -$90M | -$51M | -$47M | -$64M | -$89M |
| Interest expense | — | — | — | — | $4M | $4M | $736,000 | $418,000 | $4M | $4M |
| Pre-tax income | — | — | — | — | — | — | — | — | -$64M | $71M |
| Income tax | $0 | $0 | $0 | — | — | — | — | — | — | $100,000 |
| Net income | -$22M | -$27M | -$57M | -$76M | -$84M | -$85M | -$40M | -$54M | -$64M | $71M |
| EPS (diluted) | -$16.00 | -$16.50 | -$29.75 | -$37.75 | -$22.75 | -$21.50 | -$5.53 | -$2.53 | -$1.55 | $1.01 |
| Diluted shares | 1M | 2M | 2M | 2M | 4M | 4M | 8M | 21M | 41M | 66M |
| Gross margin | — | — | — | — | — | — | — | — | — | 73.7% |
| Operating margin | -2686.3% | -3325.7% | -1940.2% | — | -814.2% | -2994.5% | -3600.8% | -1346.7% | — | -1536.9% |
| Net margin | -2460.4% | -3263.9% | -1890.3% | — | -842.3% | -2831.2% | -2807.4% | -1548.2% | — | 1223.1% |
Balance sheet
Fiscal years, from Abeona Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $69M | $138M | $85M | $129M | $95M | $51M | $52M | $53M | $98M | $191M |
| Receivables | $124,000 | $107,000 | $81,000 | — | — | $3M | — | — | — | $6M |
| Inventory | — | — | — | — | — | — | — | — | — | $5M |
| Total current assets | $69M | $141M | $89M | $132M | $98M | $56M | $53M | $56M | $101M | $205M |
| Property, plant and equipment | $721,000 | $1M | $9M | $13M | $11M | $12M | $6M | $4M | $4M | $10M |
| Goodwill | $32M | $32M | $32M | $32M | $32M | — | — | — | — | — |
| Total assets | $111M | $179M | $174M | $223M | $151M | $80M | $64M | $64M | $109M | $220M |
| Total current liabilities | $8M | $6M | $20M | $39M | $42M | $17M | $8M | $13M | $17M | $30M |
| Long-term debt | — | — | — | — | — | — | — | — | $13M | $8M |
| Total liabilities | $12M | $9M | $40M | $45M | $49M | $37M | $37M | $49M | $65M | $60M |
| Shareholders' equity | $99M | $170M | $134M | $178M | $103M | $42M | $27M | $15M | $44M | $159M |
| Net debt | -$69M | -$138M | -$19M | -$129M | -$13M | -$33M | -$14M | -$14M | -$4M | -$58M |
Cash flow
Fiscal years, from Abeona Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13M | -$23M | -$39M | -$63M | -$35M | -$66M | -$43M | -$37M | -$56M | -$76M |
| Capital spending | $519,000 | $860,000 | $9M | $6M | $1M | $4M | $130,000 | $331,000 | $2M | $8M |
| Free cash flow | -$14M | -$24M | -$48M | -$69M | -$36M | -$70M | -$44M | -$37M | -$58M | -$84M |
| Stock-based compensation | $5M | $5M | $8M | $7M | $6M | $9M | $3M | $5M | $7M | $11M |
| Net borrowing | — | — | — | — | — | — | — | — | $20M | — |
| Free cash flow margin | -1522.3% | -2809.4% | -1612.9% | — | -363.6% | -2327.2% | -3084.4% | -1066.9% | — | -1448.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ABEO.
Open ABEO in InvestinglyQuestions
What was Abeona Therapeutics's revenue in 2025?
$6M in fiscal 2025, from its 10-K filing.
How much free cash flow does Abeona Therapeutics generate?
-$84M in fiscal 2025 (operating cash flow minus capital spending).
From Abeona Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.